Compare Eli Lilly And Co (LLY) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs J M Smucker Co — how do they compare? Eli Lilly And Co trades at $1,160.92 (market cap $1.02T), while J M Smucker Co trades at $113.71 (market cap $11.97B). The key difference: Eli Lilly And Co is far larger — about 85.2× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.93%). Which is the better fit depends on your goals.
| LLY | SJM | |
|---|---|---|
Market Cap | $1.02T | $11.97B |
Sector | Health | Consumer Staples |
52-Week High | $1.24K | $117.05 |
52-Week Low | $625.65 | $89.53 |
Enterprise Value | $1.06T | $19.00B |
Dividend Yield | 0.6% | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
J.M. Smucker (SJM) trades at $112.66, up 0.58% today, with a bullish technical signal and strong analyst consensus. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 results are pending. The company maintains a solid dividend, recently increased to $1.12 per share, and benefits from growth in Uncrustables and coffee segments. However, negative net income margin and ROE highlight profitability challenges amid revenue growth to $8.73 billion in 2025.
SJM presents a mixed outlook: valuation metrics like P/E of 22.05 and P/S of 1.32 suggest reasonable pricing, but persistent net losses and high debt pose risks. Analyst price targets average $123.18, implying upside, yet investors must weigh competitive pressures and volatile cash flows against dividend stability and brand strength in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
